Replimune Group (NASDAQ:REPL) Stock Price Down 3.5% – Here’s What Happened

Shares of Replimune Group, Inc. (NASDAQ:REPL) were down 3.5% during trading on Friday . The stock traded as low as $13.14 and last traded at $13.27. Approximately 92,520 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 869,392 shares. The stock had previously closed at $13.75.

Analyst Ratings Changes

REPL has been the subject of several analyst reports. Jefferies Financial Group lifted their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. BMO Capital Markets boosted their price target on Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, HC Wainwright lifted their price objective on Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a report on Wednesday. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $19.14.

Replimune Group Stock Down 3.7 %

The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a 50 day moving average of $12.18 and a two-hundred day moving average of $11.28. The firm has a market capitalization of $905.88 million, a price-to-earnings ratio of -4.35 and a beta of 1.28.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. As a group, sell-side analysts anticipate that Replimune Group, Inc. will post -2.88 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares in the company, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Large investors have recently modified their holdings of the business. Point72 DIFC Ltd bought a new stake in shares of Replimune Group in the second quarter worth $57,000. Erste Asset Management GmbH bought a new stake in shares of Replimune Group in the 3rd quarter valued at about $133,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Replimune Group by 82.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after buying an additional 5,926 shares during the period. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company’s stock worth $165,000 after acquiring an additional 6,748 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Replimune Group in the third quarter worth approximately $222,000. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.